Valneva Announces Retirement of Chief Financial Officer David Lawrence
18 Settembre 2020 - 7:00AM
Saint-Herblain (France),
September 18, 2020 – Valneva SE (“Valneva”), a specialty
vaccine company focused on prevention of diseases with major unmet
needs, today announced the retirement of its Chief Financial
Officer, David Lawrence, at the end of 2020.
The Company has initiated a search process with
a leading global recruitment agency to identify a new CFO, aiming
for an on-boarding in the first quarter of 2021.
Until the end of the year, David will manage a
handover process to ensure a smooth transition with Manfred
Tiefenbacher, VP Finance, who will assume responsibility for all
operational finance matters.
In addition, David has agreed to continue to
support Valneva’s CEO in an advisory capacity in the early part of
2021.
Thomas Lingelbach, Chief Executive
Officer of Valneva, said, “We would like to thank David
for his great contributions to the Company and its strategic
development over the past three years. He has played a pivotal role
in building and executing the Company’s capital formation strategy
and most recently in our global COVID-19 efforts including, in
particular, the wonderful partnership with the UK government. We
wish him well in his retirement.”
David Lawrence, Chief Financial Officer
of Valneva, said, “The last three years with Valneva have
been extremely exciting and rewarding. For personal reasons, I have
decided to retire at the end of the year. I am handing over the CFO
role with solid financials and with a great team. Valneva has
tremendous prospects and I am looking forward to watching its
future successes.”
About Valneva SEValneva is a
specialty vaccine company focused on prevention against diseases
with major unmet needs. Valneva’s portfolio includes two commercial
vaccines for travelers: IXIARO®/JESPECT® indicated for the
prevention of Japanese encephalitis and DUKORAL® indicated for the
prevention of cholera and, in some countries, prevention of
diarrhea caused by ETEC. The Company has various vaccines in
development including unique vaccines against Lyme disease,
chikungunya and COVID-19. Valneva has operations in Austria,
Sweden, the United Kingdom, France, Canada and the US with over 500
employees. For more information, visit www.valneva.com and
follow the Company on LinkedIn.
Valneva
Investor and Media ContactsLaetitia
Bachelot-FontaineDirector Investor Relations & Corporate
CommunicationsM +33 (0)6 4516
7099investors@valneva.com |
|
Valneva Forward-Looking Statements
This press release contains certain
forward-looking statements relating to the business of Valneva,
including with respect to the progress, timing and completion of
research, development and clinical trials for product candidates,
the ability to manufacture, market, commercialize and achieve
market acceptance for product candidates, the ability to protect
intellectual property and operate the business without infringing
on the intellectual property rights of others, estimates for future
performance and estimates regarding anticipated operating losses,
future revenues, capital requirements and needs for additional
financing. In addition, even if the actual results or development
of Valneva are consistent with the forward-looking statements
contained in this press release, those results or developments of
Valneva may not be indicative of their in the future. In some
cases, you can identify forward-looking statements by words such as
"could," "should," "may," "expects," "anticipates," "believes,"
"intends," "estimates," "aims," "targets," or similar words. These
forward-looking statements are based largely on the current
expectations of Valneva as of the date of this press release and
are subject to a number of known and unknown risks and
uncertainties and other factors that may cause actual results,
performance or achievements to be materially different from any
future results, performance or achievement expressed or implied by
these forward-looking statements. In particular, the expectations
of Valneva could be affected by, among other things, uncertainties
involved in the development and manufacture of vaccines, unexpected
clinical trial results, unexpected regulatory actions or delays,
competition in general, currency fluctuations, the impact of the
global and European credit crisis, and the ability to obtain or
maintain patent or other proprietary intellectual property
protection. In light of these risks and uncertainties, there can be
no assurance that the forward-looking statements made during this
presentation will in fact be realized. Valneva is providing the
information in these materials as of this press release, and
disclaim any intention or obligation to publicly update or revise
any forward-looking statements, whether as a result of new
information, future events, or otherwise.
- 2020_09_18_VLA_CFO_Retirement_PR_EN_Final